← Back to Search

Written Exposure Therapy for PTSD in Veterans with Substance Use Disorders (WET Trial)

N/A
Recruiting
Led By Sarah Meshberg-Cohen, PhD MS BS
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Meets DSM-5 criteria for PTSD;
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12-week post-baseline follow-up
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if writing about traumatic experiences (WET) helps Veterans with both substance use issues and PTSD more than other treatments. Veterans will either write about their trauma or a neutral topic over several sessions. The study aims to see if WET can improve PTSD and substance use outcomes. Written Exposure Therapy (WET) is a treatment for PTSD developed through systematic evaluations of expressive writing, requiring limited patient and therapist time with no between-session assignments.

Who is the study for?
This trial is for Veterans approved for substance use disorder (SUD) treatment at VA Connecticut Healthcare System, aged 18 or older, who have both SUD and PTSD. It's not open to those with schizophrenia-type disorders, current severe suicidal or homicidal risks, recent PTSD psychotherapy within the past 6 months, or literacy issues.
What is being tested?
The study tests Written Exposure Therapy (WET), a brief trauma-focused intervention aimed at treating PTSD in Veterans with co-occurring SUD. Participants will be compared to those writing on neutral topics to see if WET leads to better outcomes.
What are the potential side effects?
While specific side effects are not listed for this psychological therapy trial, participants may experience discomfort recalling traumatic events during WET sessions which could temporarily increase stress or anxiety levels.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with PTSD.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12-week post-baseline follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12-week post-baseline follow-up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
PTSD Checklist for DSM-5 (PCL-5)
Secondary study objectives
Timeline Follow-Back (TLFB)

Side effects data

From 2023 Phase 2 trial • 16 Patients • NCT04889664
85%
Fatigue
69%
Other
38%
Headache
38%
Dizziness
23%
Blurred Vision
15%
Difficulty Sleeping
15%
Menstrual Irregularity
15%
Frequent Urination
15%
Nausea/vomiting
8%
Increased Perspiration
8%
Anxiety
8%
Decreased energy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ketamine and Written Exposure Therapy

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Written Exposure TherapyExperimental Treatment1 Intervention
Written Exposure Therapy (WET) plus Treatment As Usual (TAU). WET is a 5 session, evidence-based trauma-focused written narrative exposure treatment. At each session, patients are instructed to write about the same trauma event and therapists provide feedback about adherence and offer suggestions. The first session includes psychoeducation about PTSD and a treatment rationale prior to general trauma narrative writing instructions, and specific instructions for completing the first writing session, before completing the first writing (30 minutes) session. Participants are instructed to write about the same trauma event at each following session, with an emphasis on delving into their deepest emotions and thoughts, in as much detail as possible, about the event. All writing sessions begin with specific instructions from the therapist followed by 30 minutes of writing by the participant.
Group II: Neutral Topic WritingActive Control1 Intervention
Treatment As Usual (TAU) augmented by a neutral topic writing condition. The neutral topic writing condition involves writing about an assigned topic during each of the five writing sessions. As opposed to writing about trauma, the specific focus of this condition is on writing for 30 minutes about topics related to their life without writing about emotions or opinions. Rather, they are asked to write about specific objects or events in detail, as accurately as possible, and with as much description as possible. All writing sessions begin with specific instructions from the therapist followed by 30 minutes of writing by the participant.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Written Exposure Therapy
2021
Completed Phase 2
~370

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Substance Use Disorder (SUD) include Cognitive Behavioral Therapy (CBT), Motivational Enhancement Therapy (MET), and Contingency Management (CM). CBT helps patients identify and modify negative thought patterns and behaviors associated with substance use, enhancing coping strategies. MET focuses on increasing the patient's motivation to change by resolving ambivalence about substance use. CM uses positive reinforcement, such as vouchers or rewards, to encourage abstinence and adherence to treatment. These therapies are crucial for SUD patients as they address both the psychological and behavioral aspects of addiction, which is particularly important for those with co-occurring conditions like PTSD. Effective treatment can reduce substance use and improve overall mental health, aiding in long-term recovery.
Psychotherapy and addiction: a survey of journals.Efficacy of "seeking safety" in a Dutch population of traumatized substance-use disorder outpatients: study protocol of a randomized controlled trial.

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,668 Previous Clinical Trials
3,765,696 Total Patients Enrolled
Sarah Meshberg-Cohen, PhD MS BSPrincipal InvestigatorVA Connecticut Healthcare System West Haven Campus, West Haven, CT

Media Library

Written Exposure Therapy Clinical Trial Eligibility Overview. Trial Name: NCT05327504 — N/A
Substance Use Disorder Research Study Groups: Written Exposure Therapy, Neutral Topic Writing
Substance Use Disorder Clinical Trial 2023: Written Exposure Therapy Highlights & Side Effects. Trial Name: NCT05327504 — N/A
Written Exposure Therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05327504 — N/A
~87 spots leftby May 2027